Therapies

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

4 days ago   |   By Xconomy

An Arrowhead Pharmaceuticals drug for a rare liver disease now has early Phase 2 results and the data so far look good. Not only did the therapy reduce levels of a mutant protein associated with the disorder, but patients also showed improvements in several biological measures of liver injury. The results are for just four patients from a small 16-patient study testing the drug, ARO-AAT, as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. But the early results are an encouraging sign for Arrowhead and its approach to treating inherited diseases by stopping...
Read more ...

 


Search by Tags

   Therapies      RNAi      Protein      Pharmaceutical      Pharmaceuticals      Pharma      Biology      Biologic      Biological      Genes      Drug      Drugs      Gene      Boston blog main      Boston top stories      National blog main      Wisconsin      Wisconsin blog main      Wisconsin top stories      Alnylam Pharmaceuticals      Alpha 1-antitrypsin deficiency      American Association for the Study of Liver Disease      Arrowhead Pharmaceuticals      Biotech      Cardiovascular Disease      Clinical trials      Dicerna Pharmaceuticals      FDA      Fibrosis      Hepatitis B      Javier San Martin      Life Sciences      Mani Foroohar      National Organization for Rare Disorders      RNA Interference      SVB Leerink  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal

Grail is set to be acquired for $8 billion by Illumina, the gene sequencing giant that formed the cancer diagnostics developer and spun it out as a separate company four years... Read more ...

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

Xconomy Awards On-Demand ‘Meet the Finalists' Webcast Series Continues This Week

The 2020 National Xconomy Awards complimentary two-week, 11-part, on-demand Meet the Finalists daily webcast series continues this Tuesday and Wednesday at 11 a.m. ET... Read more ...

105837 Clinical Research Associate

NEUROSCIENCES Salary commensurate with qualifications and experienceFiling Deadline: Mon 10/5/2020... Read more ...

Cend Therapeutics Announces Acquisition of Impilo Therapeutics

SAN DIEGO, Sept. 21, 2020 - Cend Therapeutics, Inc., a clinical-stage biotech company, announced today that it has acquired Impilo Therapeutics, Inc. The combination expands... Read more ...

SDBN Podcast: What is a Sales Agent and Do You Need One?

I met Owen Swift at an online networking event. I didn't know what a sales agent was or why a company would choose to use one, so I invited him to the podcast to explain... Read more ...

Your cells look young for their age, compared to a chimp's

Many humans live to see their 80s, some even reach 100. But chimpanzees rarely make it past 50, despite sharing 99% of our genetic code. While modern medicine has added years... Read more ...

Flagship Pioneering's 2-becomes-one biotech nabs ex-Pfizer CSO as research lead

Flagship Pioneering's 2-becomes-one biotech nabs ex-Pfizer CSO as research lead badams Mon, 09/21/2020 - 08:20 Read more ...

Peace Pilot Completes Pole-to-Pole Circumnavigation During Pandemic

SAN DIEGO-- citizenoftheworld-San Diego pilot & former Naval officer Robert DeLaurentis returns from global Pole-to-Pole peace mission. Sept. 21 named Citizen of the World Day.... Read more ...

Two wild weeks for Grail end in $8B Illumina buyout

Grail's whirlwind two weeks have ended in the wealthy arms of its former founder and benefactors. Illumina has shelled out $8 billion to reacquire the closely-watched liquid... Read more ...

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

SAN DIEGO & MENLO PARK, Calif.--- $ILMN ILMN-Illumina, Inc. and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have... Read more ...